Candel Therapeutics (CADL) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.09
- EPS estimate
- −$0.16
- EPS surprise
- +45.02%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 14, 2025
Candel Therapeutics last reported fiscal Q2 2025 results on August 14, 2025. The company posted a loss of $0.09 per share, narrower than the estimated loss of $0.16, a 45.02% beat. The table shows no revenue and no revenue estimate for the quarter. A year earlier, in Q2 2024, the loss was $0.74 per share.
Losses run through almost the whole table. Of the 17 quarters shown, 15 were losses. The two profits were Q4 2021 at $0.05 and Q1 2025 at $0.13 per share, and the widest loss was $1.46 in Q2 2021. Full-year losses grew from $0.65 per share in 2022 to $1.30 in 2023 and $1.75 in 2024. Revenue appears only in a few 2021 and 2022 quarters, at about $31,000 to $32,000. Against estimates the record is mixed, with 8 beats and 6 misses. No estimate was given for the first three quarters of 2024.
The table ends with Q2 2025 and holds no later quarter. In earlier years, Candel reported third-quarter results between November 9 and November 14 and fourth-quarter results in March. Newer quarters, once they appear here, will show whether results stay closer to break-even, as in the first half of 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | −$0.16 | −$0.09 | +45.02% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.37 | $0.13 | +134.70% | $0.00 | SEC |
| Q4 2024 | Mar 13, 2025 | −$0.23 | −$0.40 | −75.75% | $0.00 | SEC |
| Q3 2024 | Nov 14, 2024 | $0.00 | −$0.33 | +0.00% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | $0.00 | −$0.74 | +0.00% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | $0.00 | −$0.28 | +0.00% | $0.00 | SEC |
| Q4 2023 | Mar 28, 2024 | −$0.16 | −$0.38 | −137.50% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.19 | −$0.29 | −52.63% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.30 | −$0.33 | −10.52% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.35 | −$0.30 | +14.33% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.31 | −$0.18 | +41.20% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.35 | −$0.30 | +15.13% | $31,000.00 | — |
| Q2 2022 | Aug 5, 2022 | −$0.39 | −$0.14 | +64.27% | $31,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.09 | −$0.03 | +66.25% | $0.00 | SEC |
| Q4 2021 | Mar 29, 2022 | −$0.31 | $0.05 | +116.22% | $32,000.00 | SEC |
| Q3 2021 | Nov 12, 2021 | −$0.26 | −$0.69 | −163.96% | $31,000.00 | SEC |
| Q2 2021 | Sep 8, 2021 | −$0.23 | −$1.46 | −535.61% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Candel Therapeutics (CADL) last report earnings?
Candel Therapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did CADL beat earnings estimates?
Yes. Candel Therapeutics reported EPS of −$0.09 for Q2 2025 against a −$0.16 estimate — a 45.02% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.